history
One injection, eight hours, and a second drug hiding inside Melanotan II
The most consequential thing anyone ever discovered about Melanotan II wasn’t the tan. It was what happened when a researcher gave himself too much of it.
The self-experiment
By the late 1980s the University of Arizona team had their cyclic analog in hand and a straightforward question: did it tan a human being the way it tanned laboratory animals? To find out, members of the lab tested it on themselves. As the story is usually told — and it has been told many times — one of the researchers, the biologist Mac Hadley, received roughly double the intended amount. He developed severe nausea and an erection that lasted some eight hours.
The tan, presumably, also arrived. Nobody remembers the story for the tan.
What the accident actually revealed
An eight-hour erection meant the peptide was not staying politely in the skin. It was reaching the brain — the central melanocortin receptors, MC4R chief among them, that sit in the circuits governing sexual arousal. Melanotan II wasn’t a tanning agent with an odd quirk. It was a whole-body melanocortin signal, and arousal was simply one of the many things that signal does when you shout it (one hormone, five receptors).
That reframing — from “tanning drug” to “systemic melanocortin agonist” — is the hinge the entire commercial history turns on.
From side effect to franchise
Palatin Technologies licensed Melanotan II to develop exactly this effect. Around 2000 the company stopped developing MT-II itself and built bremelanotide, sold as PT-141 in its research years — a close relative (very likely a metabolite of MT-II, carrying a hydroxyl group where MT-II carries an amide) deliberately tuned toward the central receptors and away from the MC1R tanning action of its parent. Bremelanotide became Vyleesi, approved by the FDA in 2019 for hypoactive sexual desire disorder in premenopausal women.
A tanning peptide’s overdose, in other words, became a purpose-built drug for female sexual desire. That is not a metaphor for the Melanotan story. It is the Melanotan story, happening for the first time.
The lawsuit over the leftovers
Even the scraps were valuable. Competitive Technologies — the technology- transfer company that handled the University of Arizona’s patents — sued Palatin over the rights to what came out of the program. They settled in 2008: Palatin kept bremelanotide, handed the rights to Melanotan II back, and paid $800,000. Two companies went to court over ownership of a compound one of them had already abandoned.
The pattern this set
The accident established the template every later chapter would follow. The value of Melanotan II kept turning out to live in its side effects — arousal, appetite, and later the pigment work of its siblings — each one spun off into a targeted medicine for something other than the durable protective tan the molecule was built to deliver. The story of Melanotan II is a story told almost entirely in its by-products. It started here, with one researcher, one oversized injection, and a very long afternoon.